2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - New Orleans Theatre B
Technology and Procedures, Imaging, Treatment Considerations, Therapy Sequence, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries
PAPER

521 Standardizing Lugano response criteria: An aggregate analysis of discordant PET and CT progression assessments

Ben Byrne, Iris To, PharmD2, Jason Sit, PharmD3, Souhila Ounadjela4, Kamila Boudier, PhD5, Lisa Musick6, Jue Wang7
1 F. Hoffmann-La Roche Ltd, Basel, Switzerland
2 Genentech, Inc., South San Francisco, California, United States
3 Genentech, Inc., South San Francisco, California, United States
4 Genentech, Inc., South San Francisco, California, United States
5 F. Hoffmann-La Roche Ltd, Basel, Switzerland
6 Genentech, Inc., South San Francisco, California, United States
7 Genentech, Inc., South San Francisco, California, United States

Background: The 2014 Lugano classification criteria (Cheson et al. 2014) are widely used to evaluate response in Hodgkin and non-Hodgkin lymphoma, incorporating anatomic response through computed tomography (CT) scans and metabolic activity through positron emission tomography (PET) scans. Although PET findings are intended to drive the overall response assessment in FDG-avid lymphomas, the criteria are not always applied consistently across clinical trials since interpretations of certain aspects may vary. Different feedback from health authorities has further contributed to variability in how responses are assessed and reported. In some regulatory reviews, health authorities have advised that a progressive disease by CT should override a non-PD assessment by PET. This raises the question as to what is appropriate when integrating PET and CT assessments presenting discordant PD outcomes.

Methods: An aggregate review of response assessments data from 17 recent sponsor-led Phase 1-3 clinical trials in non-Hodgkin lymphoma that utilized the Lugano 2014 response criteria was conducted. The primary objective was to evaluate integrated PET and CT response outcomes for scenarios where CT indicates PD while PET indicates non-PD at the same time point. Two algorithms (integrated time point response with PET priority [ITPR-PET], in which PET is always prioritized over CT; and integrated time point response with CT PD priority [ITPR-CT], in which CT PD is prioritized over a non-PD PET assessment) were compared. The analysis evaluated true and false PD rates alongside discrimination metrics, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

Results: A total of 3,278 patients from 17 clinical studies were eligible for evaluation of the two algorithms. Of these, 2,027 patients were diagnosed with diffuse large B-cell lymphoma (DLBCL), 747 with follicular lymphoma (FL) and the remaining to rarer sub-histologies. A variety of treatment regimens were included, such as chemoimmunotherapy, checkpoint inhibitors, antibody drug-conjugates, bispecific antibodies, and small molecules. 13,543 time points were considered, and 7,700 time point responses had both PET and CT responses evaluable. PET and CT assessments were discordant with respect to progression status in 208 patients across 227 time points, which included 69 cases of PET non-PD with CT PD and 158 cases of PET PD with CT non-PD. Among the 69 time points with PET non-PD and CT PD, PET failed to identify a true progression (by any raw data sources supporting PD) in 20.3% (14/69) of time points, whereas CT incorrectly identified a progression in 79.7% (55/69) of time points where there was no true progression.  Among the 158 time points with PET PD with CT non-PD, PET identified 100% of true progressions.

Beyond the raw PET and CT assessments, a comparison of the algorithms determined 151 discordant time points where ITPR-PET classified the time point response as non-PD whereas ITPR-CT classified it as PD. Of these cases, ITPR-PET failed to identify a true progression 7.3% (11/151) of the time, while ITPR-CT incorrectly identified a progression 92.7% (140/151) of the time. Across all 13,543 time points, ITPR-PET demonstrated a sensitivity of 99.3% and a positive predictive value (PPV) of 100%, compared with 99.9% and 92.0%, respectively, for ITPR-CT.

Results were also evaluated by histologic subtype. Among 2,056 patients with large B-cell lymphoma (LBCL) across 9,612 time points, ITPR-PET demonstrated a sensitivity of 99.2% and a PPV of 100%, compared with 99.9% and 94.0%, respectively, for ITPR-CT. Among 691 patients with FL across 3,052 time points, ITPR-PET demonstrated a sensitivity of 99.2% and a PPV of 100%, compared with 100% and 89.6%, respectively, for ITPR-CT.

Conclusions: The ITPR-PET algorithm, prioritizing time point PET over CT, correctly classified progression status in the vast majority of discordant cases. Compared with ITPR-CT, prioritizing CT PD over a  PET non-PD assessment), ITPR-PET substantially reduced false-positive PD classifications, with a small decrease in sensitivity. These findings support ITPR-PET as the recommended algorithm for integrating time point responses and suggest CT-defined progression should not override a non-PD assessment from a valid PET scan. The performance of both algorithms was generally consistent across histologic subtypes.
Ben Byrne: Roche Products Ltd - Current equity holder in publicly-traded company; Roche Products Ltd - Divested equity in a private or publicly-traded company in the past 24 months; Roche Products Ltd - Current Employment